The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

Journal of Diabetes and its Complications

Volumn 27, Issue 3, 2013, Pages 280-286

  Basile, Jan N ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG; URIC ACID;

BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DYSLIPIDEMIA; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; URIC ACID BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84876938443     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.12.004     Document Type: Review

References (73)

1. ACCORD Study Group Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine 358 2008 2545 2559
2. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes The New England Journal of Medicine 358 2008 2560 2572
3. American Diabetes Association Executive summary: Standards of medical care in diabetes - 2012 Diabetes Care 35 Suppl 1 2012 S4 S10
4. C.J. Bailey Renal glucose reabsorption inhibitors to treat diabetes Trends in Pharmacological Sciences 32 2 2011 63 71
5. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 9733 2010 2223 2233
6. J. Basile A new approach to glucose control in type 2 diabetes: The role of kidney sodium-glucose co-transporter 2 inhibition Postgraduate Medicine 123 4 2011 38 45
7. J. Bolinder, Ö. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, and A.M. Langkilde Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin Journal of Clinical Endocrinology and Metabolism 97 3 2012 1020 1031
8. R.K. Campbell Fate of the beta-cell in the pathophysiology of type 2 diabetes Journal of the American Pharmacists Association 49 Suppl 1 2009 S10 S15
9. W.T. Cefalu Evolving treatment strategies for the management of type 2 diabetes The American Journal of the Medical Sciences 343 1 2012 21 26
10. W.T. Cefalu American Diabetes Association-European Association for the Study of Diabetes Position Statement: Due diligence was conducted Diabetes Care 35 6 2012 1201 1203
11. W.T. Cefalu, L.A. Leiter, L. Niskanen, J. Xie, D. Millington, and W. Canovatchel Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin Diabetes 61 Suppl 1A 2012 10-LB
12. W.T. Cefalu, R.J. Richards, and L.Y. Melendez-Ramirez Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects Cleveland Clinic Journal of Medicine 76 2009 S39 S47
13. Centers for Disease Control and Prevention National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011 2011 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA
14. C. Cheeseman Solute carrier family 2, member 9 and uric acid homeostasis Current Opinion in Nephrology and Hypertension 8 5 2009 428 432
15. S. Cornell Key considerations in pharmacotherapy for type 2 diabetes mellitus: A multiple target organ approach Journal of Clinical Pharmacy and Therapeutics 37 3 2011 254 259
16. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, and C.J. Paciorek National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 9785 2011 31 40
17. R.A. DeFronzo Overview of newer agents: Where treatment is going American Journal of Medicine 123 Suppl 3 2010 S38 S48
18. R.A. DeFronzo, J.A. Davidson, and S. del Prato The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia Diabetes, Obesity & Metabolism 14 1 2012 5 14
19. C.V. DeSouza, and V. Fonseca Therapeutic targets to reduce cardiovascular disease in type 2 diabetes Nature Reviews Drug Discovery 8 5 2009 361 367
20. D. Devineni, L. Morrow, M. Hompesch, D. Skee, A. Vandebosch, and J. Murphy Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes, Obesity and Metabolism 14 6 2012 539 545
21. 1c target < 7% with 8 classes of anti-diabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78,945 patients Diabetes, Obesity and Metabolism 14 3 2012 228 233
22. European Medicines Agency Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002322/ WC500125684.pdf 2012 Accessed 15 September 2012
23. FDA briefing document, NDA 202293. (2011). Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingsMaterials/drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. Accessed 15 September 2012.
24. E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, Phase 3 trial Diabetes Care 33 10 2010 2217 2224
25. E. Ferrannini, L.J. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H.-J. Woerle The potent and highly selective sodium glucose cotransporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus Diabetologia 53 Suppl 1 2010 S351 [877]
26. E. Ferrannini, and W.C. Cushman Diabetes and hypertension: The bad companions Lancet 380 9841 2012 601 610
27. E. Ferrannini, and A. Solini SGLT-2 inhibition in diabetes mellitus: Rationale and clinical prospects Nature Reviews Endocrinology 8 8 2012 495 502
28. V. Fonseca, E. Ferrannini, J. Wilding, W. Wilpshaar, G. Ball, and S. Klasen Active-controlled dose-finding study of efficacy, safety, and tolerability of multiple doses of ipragliflozin in type 2 diabetes patients IDF World Diabetes Congress, Dubai, UAE, December 5-9, Abstract O-0592 2011
29. C. Foote, V. Perkovic, and B. Neal Effects of SGLT-2 inhibitors on cardiovascular outcomes Diabetes and Vascular Disease Research 9 2 2012 117 123
30. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications Diabetic Medicine 27 2 2010 136 142
31. E.W. Gregg, Y.J. Cheng, K.M. Narayan, T.J. Thompson, and D.F. Williamson The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976-2004 Preventive Medicine 45 5 2007 348 352
32. J.L. Gross, G. Schernthaner, M. Fu, S. Patel, M. Kawaguchi, and W. Canovatchel Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea Diabetes 61 Suppl 1A 2012 LB13 LB14 [50-LB]
33. R.R. Henry, A.V. Murray, M.H. Marmolejo, D. Hennicken, A. Ptaszynska, and J.F. List Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial International Journal of Clinical Practice 66 5 2012 446 456
34. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes The New England Journal of Medicine 359 15 2008 1577 1589
35. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: Scientific review Journal of the American Medical Association 287 2002 360 372
36. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 6 2012 1364 1379
37. F. Ismail-Beigi, T. Craven, M.A. Banerji, J. Basile, J. Calles, and R.M. Cohen Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial Lancet 376 9739 2010 419 430
38. G. Kabakci, N. Koylan, B. Ilerigelen, O. Kozan, and K. Buyukozturk Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: Results from the ICEBERG study Integrated Blood Pressure Control 1 2008 5 13
39. A. Kashiwagi, Y. Takinami, K. Kazuta, S. Yoshida, A. Utsuno, and I. Nagase Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study Diabetologia 54 Suppl 1 2011 S68
40. T.N. Kelly, L.A. Bazzano, V.A. Fonseca, T.K. Thethi, K. Reynolds, and J. He Systematic review: glucose control and cardiovascular disease in type 2 diabetes Annals of Internal Medicine 151 6 2011 394 403
41. S. Klein, N.F. Sheard, X. Pi-Sunyer, A. Daly, J. Wylie-Rosett, and K. Kulkarni Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition American Journal of Clinical Nutrition 80 2004 257 263
42. D.E. Kohan, P. Fioretto, J. List, and W. Tang Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment Journal of the American Society of Nephrology 22 2011 232A
43. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 4 2009 650 657
44. J.F. List, and J.M. Whaley Glucose dynamics and mechanistic implications of SGLT-2 inhibitors in animals and humans Kidney International Suppl 120 2011 S20 S27
45. R. Madonna, and R. De Caterina Cellular and molecular mechanisms of vascular injury in diabetes - part I: Pathways of vascular disease in diabetes Vascular Pharmacology 54 3-6 2011 68 74
46. E. Marrett, T. Stargardt, P. Mavros, and C.M. Alexander Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: Associations with hypoglycaemia and weight gain Diabetes, Obesity & Metabolism 11 2009 1138 1144
47. A. Mather, and C. Pollock Glucose handling by the kidney Kidney International Suppl 120 2011 S1 S6
48. G. Musso, R. Gambino, M. Cassader, and G. Pagano A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials Annals of Medicine 44 2011 375 393
49. M.A. Nauck, S. del Prato, J.J. Meier, S. Durán-García, K. Rohwedder, and M. Elze Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled non-inferiority trial Diabetes Care 34 9 2011 2015 2022
50. L.E. Nicolle, G. Capuano, K. Ways, and K. Usiskin Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study Current Medical Research and Opinion 28 7 2012 1167 1171
51. C.J. Nolan, P. Damm, and M. Prentki Type 2 diabetes across generations: From pathophysiology to prevention and management Lancet 378 9786 2011 169 181
52. P. Nyirjesy, Y. Zhao, K. Ways, and K. Usiskin Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor Current Medical Research and Opinion 28 7 2012 1173 1178
53. 1c goal attainment Current Medical Research and Opinion 24 9 2008 2523 2529
54. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 12 2005 3427 3434
55. J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, and K. Usiskin Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 6 2012 1232 1238
56. J. Rosenstock, A. Jelaska, L. Seman, S. Pinnetti, S. Hantel, and H.J. Woerle Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin Diabetes 60 2011 A271 [989-P]
57. J. Rosenstock, M. Vico, L. Wei, A. Salsali, and J.F. List Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 7 2012 1473 1478
58. G. Schernthaner, A.H. Barnett, D.J. Betteridge, R. Carmena, A. Ceriello, and B. Charbonnel Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis Diabetologia 53 7 2010 1258 1269
59. S.L. Schwartz, B. Akinlade, S. Klasen, D. Kowalski, W. Zhang, and W. Wilpshaar Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus Diabetes Technology and Therapeutics 13 12 2011 1219 1227
60. K. Strojek, K.H. Yoon, V. Hruba, M. Elze, A.M. Langkilde, and S. Parikh Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial Diabetes, Obesity and Metabolism 13 10 2011 928 938
61. A.A. Tahrani, M.K. Piya, A. Kennedy, and A.H. Barnett Glycaemic control in type 2 diabetes: Targets and new therapies Pharmacology and Therapeutics 125 2 2010 328 361
62. T. Terry, K. Raravikar, N. Chokrungvaranon, and P.D. Reaven Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT Current Cardiology Reports 14 1 2012 79 88
63. M. Tobias Global control of diabetes: Information for action Lancet 378 9785 2011 3 4
64. The Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
65. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group Journal of the American Medical Association 281 21 1999 2005 2012
66. J.P. Wilding, P. Norwood, C. T'joen, A. Bastien, J.F. List, and F.T. Fiedorek A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment Diabetes Care 32 9 2009 1656 1662
67. J.P. Wilding, V. Woo, N.G. Soler, A. Pahor, J. Sugg, and K. Rohwedder Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial Annals of Internal Medicine 156 6 2012 405 415
68. J.P.H. Wilding, E. Ferrannini, F. Fonseca, W. Wilpshaar, A. Houzer, and A. de Torbal Efficacy and safety of ipragliflozin in type 2 diabetes patients inadequately controlled on metformin: a dose-finding study IDF World Diabetes Congress, December 5-9, Dubai, UAE, Abstract [D-0741] 2011
69. H.J. Woerle, E. Ferrannini, A. Berk, M. Manun'ebo, S. Pinnetti, and U.C. Broedl Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes Diabetes 61 Suppl 1A 2012 LB13 [49-LB]
70. E.M. Wright, B.A. Hirayama, and D.F. Loo Active sugar transport in health and disease Journal of Internal Medicine 261 1 2007 32 43
71. J.F. Yale, G. Bakris, L. Xi, K. Figueroa, E. Wajs, and K. Usiskin Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment Diabetes 61 Suppl 1A 2012 41-LB [LB-41]
72. L. Zhang, Y. Feng, J. List, S. Kasichayanula, and M. Pfister Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight Diabetes, Obesity and Metabolism 12 6 2010 510 516
73. G. Zoppini, G. Targher, C. Negri, V. Stoico, F. Perrone, and M. Muggeo Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients Diabetes Care 32 9 2009 1716 1720